During the past decade, Melbourne Gastrointestinal Investigation Unit (MGIU) conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 2 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Melbourne Gastrointestinal Investigation Unit (MGIU)" are "Ulcerative Colitis" (2 trials). Many other conditions were trialed in "Melbourne Gastrointestinal Investigation Unit (MGIU)" in a lesser frequency.

Most popular intervention types in "Melbourne Gastrointestinal Investigation Unit (MGIU)" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Mirikizumab" (1 trials), "Mirikizumab IV" (1 trials), "Mirikizumab SC" (1 trials), "Placebo" (1 trials) and "Placebo SC" (1 trials). Other intervention names were less common.

The vast majority of trials in "Melbourne Gastrointestinal Investigation Unit (MGIU)" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Melbourne Gastrointestinal Investigation Unit (MGIU)". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Melbourne Gastrointestinal Investigation Unit (MGIU), undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Melbourne Gastrointestinal Investigation Unit (MGIU), 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".